MedTrace Logo

Alirocumab and Plaque Burden In Familial Hypercholesterolaemia

NCT05465278 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2022-07-19

No results posted yet for this study

Summary

Low-level, open-label, multicenter clinical trial to evaluate the effect of alirocumab on the volume, architecture and composition of atherosclerotic plaque in patients with Familial hypercholesterolemia from the SAFEHEART Registry. ARCHITECT study

Conditions

  • Familial Hypercholesterolemia

Interventions

DRUG

Alirocumab

18 months treatment with alirocumab

Sponsors & Collaborators

  • Fundación Hipercolesterolemia Familiar

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2022-03-30
Completion
2022-03-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05465278 on ClinicalTrials.gov